96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis... von Loibl, S., Huang, C-S., Mano, M.S., Mamounas, T.P., Geyer, C.E., Untch, M., von Minckwitz, G., Thery, J-C., Schwaner, I., Limentani, S., Loman, N., Lübbe, K., Chang, J.C., Hatschek, T., Tesarowski, D., Boulet, T., Wiese, C., Song, C., Wolmark, N.

Volltext